Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Dosing interval
Immunotherapy
Oncology
Pharmacokinetics
Therapeutic antibodies
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
15 01 2022
15 01 2022
Historique:
received:
18
05
2021
accepted:
26
08
2021
entrez:
16
1
2022
pubmed:
17
1
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Anti-CTLA-4 and anti-PD-1/PD-L1 immune checkpoint inhibitors are therapeutic monoclonal antibodies that do not target cancer cells but are designed to reactivate or promote antitumor immunity. Dosing and scheduling of these biologics were established according to conventional drug development models, even though the determination of a maximum tolerated dose in the clinic could only be defined for anti-CTLA-4. Given the pharmacology of these monoclonal antibodies, their high interpatient pharmacokinetic variability, the actual clinical benefit as monotherapy that is observed only in a specific subset of patients, and the substantial cost of these treatments, a number of questions arise regarding the selected dose and the dosing interval. This review aims to outline the development of these immunotherapies and considers optimization options that could be used in clinical practice.
Identifiants
pubmed: 35033167
doi: 10.1186/s13045-021-01182-3
pii: 10.1186/s13045-021-01182-3
pmc: PMC8760805
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6Informations de copyright
© 2021. The Author(s).
Références
Lancet Oncol. 2017 May;18(5):587-598
pubmed: 28373007
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Hematol Oncol. 2020 Dec;38(5):726-736
pubmed: 32786092
Ann Oncol. 2016 Jul;27(7):1291-8
pubmed: 27117531
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):415-427
pubmed: 30980481
Ann Oncol. 2019 Apr 1;30(4):644-651
pubmed: 30715147
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059432
Ann Oncol. 2018 Nov 1;29(11):2208-2213
pubmed: 30215677
Front Immunol. 2018 Sep 20;9:2140
pubmed: 30294328
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Clin Pharmacokinet. 2019 Jul;58(7):835-857
pubmed: 30815848
Lancet Oncol. 2018 Apr;19(4):451-460
pubmed: 29530667
CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):49-57
pubmed: 27863186
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
J Immunother. 2006 Jul-Aug;29(4):455-63
pubmed: 16799341
Eur J Cancer. 2016 Nov;68:156-162
pubmed: 27764686
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Cancer Med. 2020 Oct;9(19):6923-6932
pubmed: 32412157
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
BMC Cancer. 2019 Nov 14;19(1):1102
pubmed: 31727024
J Immunother Cancer. 2016 Nov 15;4:70
pubmed: 27879972
Clin Pharmacokinet. 2020 Mar;59(3):287-296
pubmed: 31701469
J Clin Pharmacol. 2017 Oct;57 Suppl 10:S26-S42
pubmed: 28921644
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Blood. 2017 May 4;129(18):2471-2478
pubmed: 28270452
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
J Clin Oncol. 2017 Aug 20;35(24):2781-2789
pubmed: 28609226
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
J Clin Oncol. 2013 Dec 1;31(34):4311-8
pubmed: 24145345
Eur J Cancer. 2020 May;131:68-75
pubmed: 32305010
Vaccines (Basel). 2020 Oct 31;8(4):
pubmed: 33142728
Lancet. 2014 Sep 20;384(9948):1109-17
pubmed: 25034862
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Chemother Pharmacol. 2019 Dec;84(6):1153-1155
pubmed: 31630223
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Eur J Clin Pharmacol. 2021 Jan;77(1):87-93
pubmed: 32808071
J Immunother Cancer. 2017 Feb 21;5:20
pubmed: 28239472
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
J Clin Pharmacol. 2017 Dec;57(12):1527-1533
pubmed: 28800166
Eur J Cancer. 2018 Sep;101:114-122
pubmed: 30053670
MAbs. 2016;8(3):593-603
pubmed: 26918260
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32554615
J Clin Oncol. 2005 Sep 1;23(25):6043-53
pubmed: 16087944
J Clin Pharmacol. 2009 Sep;49(9):1012-24
pubmed: 19620385
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Clin Pharmacol Ther. 2018 Apr;103(4):631-642
pubmed: 29243223
Ann Surg Oncol. 2005 Dec;12(12):1005-16
pubmed: 16283570
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
J Glob Oncol. 2019 Jul;5:1-5
pubmed: 31348737
Clin Pharmacol Ther. 2020 Mar;107(3):588-596
pubmed: 31553054
Clin Cancer Res. 2018 Dec 1;24(23):5841-5849
pubmed: 29891725
Br J Clin Pharmacol. 2020 Sep;86(9):1769-1777
pubmed: 32424951
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Br J Clin Pharmacol. 2019 Sep;85(9):2045-2058
pubmed: 31140642
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Clin Oncol. 2015 Jun 20;33(18):2013-20
pubmed: 25800770
Lancet Oncol. 2017 Feb;18(2):212-220
pubmed: 28081914
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Lancet Oncol. 2016 Mar;17(3):299-308
pubmed: 26858122
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
J Immunother Cancer. 2016 Nov 15;4:72
pubmed: 27879974
Oncologist. 2017 Oct;22(10):1212-1221
pubmed: 28754722
Lancet Oncol. 2020 Jun;21(6):808-820
pubmed: 32502443
Ann Oncol. 2017 Aug 1;28(8):2002-2008
pubmed: 28520840
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Clin Cancer Res. 2015 Oct 1;21(19):4286-93
pubmed: 25977344
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
Eur J Cancer. 2019 May;113:28-31
pubmed: 30965212
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Cancer Chemother Pharmacol. 2021 Jan;87(1):53-64
pubmed: 33146741
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Clin Pharmacokinet. 2012 Feb 1;51(2):119-35
pubmed: 22257150
J Immunother Cancer. 2017 May 16;5:43
pubmed: 28515943
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Cancer Commun (Lond). 2019 Nov 21;39(1):78
pubmed: 31753015
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Clin Pharmacol Ther. 2017 May;101(5):657-666
pubmed: 28182273
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
J Clin Oncol. 2018 Aug 27;:JCO1800045
pubmed: 30148658
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Clin Pharmacol Ther. 2017 Aug;102(2):305-312
pubmed: 27981577
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Oncologist. 2017 Mar;22(3):311-317
pubmed: 28232599
Cancer Chemother Pharmacol. 2019 Dec;84(6):1257-1267
pubmed: 31542806
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
Eur Urol. 2019 Jun;75(6):961-964
pubmed: 30851984
J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):403-414
pubmed: 28573468
J Clin Oncol. 2017 Dec 1;35(34):3851-3858
pubmed: 28678668
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
J Clin Oncol. 2016 Nov 1;34(31):3733-3739
pubmed: 27354476
J Transl Med. 2011 Nov 28;9:204
pubmed: 22123319
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Lancet Oncol. 2018 Mar;19(3):405-415
pubmed: 29439857
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):21-28
pubmed: 27863143
J Clin Oncol. 2018 Jun 10;36(17):1668-1674
pubmed: 29283791
Expert Rev Clin Pharmacol. 2018 Apr;11(4):345-359
pubmed: 29478343